I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

VistaGen (VTGN) prices 1.37 M share offering at $1.75 with 1.89 M warrants attached

August 31, 2017

VTGN is down -$0.10 or -5.50% to $1.72 ​A little heavy on the warrants to raise $2.4 million ...?  

Histogenics (HSGX) P3 Clinical Trial of Neocart® enrollment completed to Treat Knee Cartilage Damage - BUY

June 27, 2017

On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019  

bluebird bio (BLUE) prices $350 M share offering at $105.00

June 26, 2017

BLUE closed down -$4.20 to $1.06.90 after Monday's -$0.90 or -0.80% to $111.10  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.